Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Stock Holdings Lifted by Cornercap Investment Counsel Inc.

Cornercap Investment Counsel Inc. raised its position in shares of Tenaya Therapeutics, Inc. (NASDAQ:TNYA) by 136.2% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 81,255 shares of the company’s stock after purchasing an additional 46,847 shares during the period. Cornercap Investment Counsel Inc. owned 0.12% of Tenaya Therapeutics worth $263,000 as of its most recent SEC filing.

Several other institutional investors have also made changes to their positions in TNYA. JPMorgan Chase & Co. raised its position in Tenaya Therapeutics by 78.9% during the first quarter. JPMorgan Chase & Co. now owns 21,876 shares of the company’s stock valued at $258,000 after acquiring an additional 9,647 shares in the last quarter. Bank of New York Mellon Corp raised its holdings in shares of Tenaya Therapeutics by 85.2% during the 1st quarter. Bank of New York Mellon Corp now owns 73,314 shares of the company’s stock valued at $864,000 after purchasing an additional 33,726 shares in the last quarter. MetLife Investment Management LLC lifted its stake in shares of Tenaya Therapeutics by 219.7% in the 1st quarter. MetLife Investment Management LLC now owns 18,722 shares of the company’s stock valued at $221,000 after purchasing an additional 12,865 shares during the last quarter. Rhumbline Advisers boosted its holdings in Tenaya Therapeutics by 124.6% in the first quarter. Rhumbline Advisers now owns 22,798 shares of the company’s stock worth $269,000 after purchasing an additional 12,646 shares in the last quarter. Finally, BlackRock Inc. increased its position in Tenaya Therapeutics by 29.7% during the first quarter. BlackRock Inc. now owns 2,428,872 shares of the company’s stock worth $28,611,000 after buying an additional 555,928 shares during the last quarter. 90.54% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Tenaya Therapeutics

In other news, insider Timothy Hoey sold 6,569 shares of the business’s stock in a transaction that occurred on Tuesday, February 20th. The stock was sold at an average price of $5.34, for a total transaction of $35,078.46. Following the sale, the insider now directly owns 236,146 shares in the company, valued at $1,261,019.64. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In related news, insider Timothy Hoey sold 6,569 shares of the company’s stock in a transaction dated Tuesday, February 20th. The shares were sold at an average price of $5.34, for a total value of $35,078.46. Following the sale, the insider now owns 236,146 shares of the company’s stock, valued at $1,261,019.64. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, major shareholder Group Gp Lp Column III purchased 2,222,222 shares of the company’s stock in a transaction that occurred on Monday, February 12th. The stock was acquired at an average cost of $4.50 per share, with a total value of $9,999,999.00. Following the transaction, the insider now directly owns 13,599,275 shares of the company’s stock, valued at $61,196,737.50. The disclosure for this purchase can be found here. Insiders sold a total of 20,908 shares of company stock valued at $122,867 in the last quarter. Corporate insiders own 33.83% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on TNYA. HC Wainwright reaffirmed a “buy” rating and issued a $18.00 price target on shares of Tenaya Therapeutics in a research report on Tuesday, March 19th. Chardan Capital reaffirmed a “buy” rating and set a $20.00 target price on shares of Tenaya Therapeutics in a research report on Thursday, March 21st. Finally, Canaccord Genuity Group dropped their price target on shares of Tenaya Therapeutics from $19.00 to $18.00 and set a “buy” rating on the stock in a research report on Wednesday, March 20th. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat, Tenaya Therapeutics currently has an average rating of “Buy” and a consensus price target of $15.40.

Tenaya Therapeutics Stock Performance

Shares of Tenaya Therapeutics stock opened at $4.30 on Thursday. Tenaya Therapeutics, Inc. has a 1 year low of $1.66 and a 1 year high of $8.09. The company’s fifty day simple moving average is $5.29 and its 200-day simple moving average is $3.57.

Tenaya Therapeutics (NASDAQ:TNYA) last announced its quarterly earnings data on Monday, March 18th. The company reported ($0.40) EPS for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.05. Equities analysts forecast that Tenaya Therapeutics, Inc. will post -1.7 earnings per share for the current year.

Tenaya Therapeutics Profile

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.